Gianantonio Rosti

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. doi request reprint Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    Gianantonio Rosti
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
    Blood 114:4933-8. 2009
  2. doi request reprint Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
    Gianantonio Rosti
    Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Italy
    Crit Rev Oncol Hematol 82:159-70. 2012
  3. doi request reprint Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
    Gianantonio Rosti
    Department of Hematology and Oncology, L and A Seragnoli, St Orsola University Hospital, University of Bologna, 9 40138 Bologna, Italy
    Cancer Treat Rev 38:241-8. 2012
  4. doi request reprint Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
    Gianantonio Rosti
    Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
    Leuk Lymphoma 51:583-91. 2010
  5. ncbi request reprint ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
  6. ncbi request reprint Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
  7. doi request reprint Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
  8. ncbi request reprint Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    Simona Soverini
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:7374-9. 2006
  9. doi request reprint Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis
    Fausto Castagnetti
    Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    J Clin Oncol 28:2748-54. 2010
  10. ncbi request reprint Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
    Simona Luatti
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 120:761-7. 2012

Collaborators

Detail Information

Publications45

  1. doi request reprint Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    Gianantonio Rosti
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna, S Orsola Malpighi Hospital, 40138 Bologna, Italy
    Blood 114:4933-8. 2009
    ..Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052...
  2. doi request reprint Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
    Gianantonio Rosti
    Department of Hematology and Oncology L and A Seràgnoli, University of Bologna, Italy
    Crit Rev Oncol Hematol 82:159-70. 2012
    ..Clinicians now have several effective options to treat patients newly diagnosed with CML-CP and available data suggest that dasatinib and nilotinib represent improved therapeutic options compared with imatinib...
  3. doi request reprint Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
    Gianantonio Rosti
    Department of Hematology and Oncology, L and A Seragnoli, St Orsola University Hospital, University of Bologna, 9 40138 Bologna, Italy
    Cancer Treat Rev 38:241-8. 2012
    ..The objectives of this article are to review the clinical management of the most frequent of these adverse events and to guide physicians in helping their patients maintain adherence and achieve optimal outcomes with nilotinib therapy...
  4. doi request reprint Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
    Gianantonio Rosti
    Department of Hematology and Oncology L e A Seragnoli, S Orsola Malpighi University Hospital, 9 40138 Bologna, Italy
    Leuk Lymphoma 51:583-91. 2010
    ..This consideration involves the differences in both the imatinib-resistant and -intolerant patients enrolled in the pivotal studies for each agent, as well as other trial criteria...
  5. ncbi request reprint ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
    ....
  6. ncbi request reprint Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  7. doi request reprint Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
    ..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial...
  8. ncbi request reprint Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    Simona Soverini
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:7374-9. 2006
    ..ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients...
  9. doi request reprint Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis
    Fausto Castagnetti
    Department of Hematology and Oncological Sciences, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    J Clin Oncol 28:2748-54. 2010
    ..For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient...
  10. ncbi request reprint Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
    Simona Luatti
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 120:761-7. 2012
    ..The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy...
  11. ncbi request reprint Imatinib mesylate in the treatment of hematologic malignancies
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
    Expert Opin Biol Ther 7:1597-611. 2007
    ..In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the above mentioned diseases...
  12. doi request reprint Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
    Fausto Castagnetti
    Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 113:3428-34. 2009
    ..These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926...
  13. ncbi request reprint Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
    Michele Baccarani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Blood 104:4245-51. 2004
    ..The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies...
  14. pmc The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 95:1415-9. 2010
    ..78%; P=0.02). These data suggest that the response to the combination treatment is more rapid. It is not yet known how much a rapid reduction will influence the longer-term overall and progression free survival, and the cure rate...
  15. ncbi request reprint Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..CCgR is durable in the majority of patients but relapse occurs in a subset...
  16. doi request reprint Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
    Simona Soverini
    Department of Hematology and Oncological Sciences L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 114:2168-71. 2009
    ....
  17. doi request reprint Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
    Giulia Marzocchi
    Department of Hematology and Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Blood 117:6793-800. 2011
    ..Therefore, we suggest that patients with variant translocations do not constitute a "warning" category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  18. ncbi request reprint Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 24:454-9. 2006
    ..Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia...
  19. pmc Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
    Francesca Palandri
    Department of Hematology and Medical Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:1758-61. 2009
    ..The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited...
  20. doi request reprint Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
    Francesca Palandri
    Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 93:770-4. 2008
    ..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance...
  21. doi request reprint Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Clin Cancer Res 15:1059-63. 2009
    ..The achievement of a major molecular response (MMolR) at 12 months is a surrogate marker of progression-free survival in chronic myeloid leukemia patients treated with imatinib...
  22. ncbi request reprint The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Haematologica 92:1173-9. 2007
    ..These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate...
  23. ncbi request reprint Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
    Simona Soverini
    Institute of Haematology and Medical Oncology L e A Seragnoli, University of Bologna, Italy
    Lancet Oncol 8:273-4. 2007
  24. doi request reprint Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
    Simona Soverini
    Department of Hematology Oncology, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Leuk Res 35:1527-9. 2011
    ..Our results suggest that a) Bcr-Abl mutations, even at low level, seem to be very rare in patients in MMR on first-line nilotinib; b) low-level mutations do not always predict for subsequent relapse...
  25. ncbi request reprint Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Chem 50:1205-13. 2004
    ..Point mutations within the ABL kinase domain are emerging as the most frequent mechanism for reactivation of kinase activity within the leukemic clone...
  26. ncbi request reprint Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Haematologica 92:101-5. 2007
    ..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients...
  27. doi request reprint Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
    Francesca Palandri
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 93:1792-6. 2008
    ..In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients...
  28. ncbi request reprint New tyrosine kinase inhibitors in chronic myeloid leukemia
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 90:534-41. 2005
    ..This review highlights the development of new TKI as specific molecularly targeted therapy and as the principal mechanisms for overcoming imatinib resistance...
  29. doi request reprint Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 113:4497-504. 2009
    ..This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488...
  30. pmc The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 94:205-12. 2009
    ..The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available...
  31. pmc Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Simona Soverini
    Department of Haematology Oncology, L e A Serígnoli, University of Bologna, Bologna, Italy
    Oncologist 16:868-76. 2011
    ..Here, we discuss the pros and cons of using this approach in TKI selection...
  32. ncbi request reprint Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
    Gianantonio Rosti
    L and A Seràgnoli Institute of Hematology and Medical Oncology, St Orsola Malpighi Hospital, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 88:256-9. 2003
    ....
  33. doi request reprint Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis
    Simona Soverini
    Department of Hematology Oncology L e A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138, University of Bologna, Bologna, Italy
    Pharmacogenomics 13:1271-84. 2012
    ..The authors also discuss the practical relevance of Bcr-Abl mutation analysis and how this tool should best be integrated in the optimal clinical management of chronic myeloid leukemia patients...
  34. ncbi request reprint Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology L and A Serànoli, University of Bologna, Italy
    Blood 103:2284-90. 2004
    ..We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet...
  35. ncbi request reprint Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 89:236-7. 2004
  36. doi request reprint Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
    Nicoletta Testoni
    Department of Hematology Oncology, L and A Seragnoli, University of Bologna and S Orsola Malpighi University Hospital, Bologna, Italy
    Blood 114:4939-43. 2009
    ..I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926...
  37. pmc Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Biologics 1:121-7. 2007
    ..Preliminary studies demonstrated that nilotinib has more efficacy than imatinib in inhibiting proliferation of BCR-ABL-dependent cells, a relatively safety profile and clinical efficacy in all phases of CML...
  38. doi request reprint Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
    Simona Soverini
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 122:1634-48. 2013
    ..Further evaluation of the clinical usefulness of UDS-based approaches is warranted. ..
  39. doi request reprint Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia
    Mario Arpinati
    Department of Hematology and Oncological Sciences Seragnoli, University of Bologna, Italy
    Biol Blood Marrow Transplant 19:735-40. 2013
    ..Fluctuation of BCR-ABL transcripts levels is common as late as ≥10 years posttransplantation, possibly suggesting the long-term persistence of CML stem cells...
  40. doi request reprint BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
    Simona Soverini
    Department of Hematology Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Blood 118:1208-15. 2011
    ..In all the cases outlined within this abstract, a positive result is an indication for therapeutic change. Some specific mutations weigh on TKI selection...
  41. pmc Imatinib in chronic myeloid leukemia elderly patients
    Gabriele Gugliotta
    Department of Hematology and Clinical Oncology Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Aging (Albany NY) 3:1125-6. 2011
    ..Although data on dasatinib and nilotinib in elderly patients are still few and the follow-up is still short, these second generation tyrosine kinase inhibitors will probably further improve the outcome of CML elderly patients...
  42. ncbi request reprint Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:688-94; discussion 694. 2002
    ..We previously described a novel type of the chimeric bcr-abl mRNA transcript in a patient with a Philadelphia chromosome positive chronic myeloid leukemia. A similar bcr-abl transcript has also been described by others...
  43. doi request reprint European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
    Michele Baccarani
    Department of Hematology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 122:872-84. 2013
    ..Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved. ..
  44. pmc First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
    Pier Paolo Piccaluga
    Hematopathology and Hematology Sections, Department of Hematology and Oncological Sciences, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Blood Med 3:151-6. 2012
    ..In this paper, we review the most relevant data on nilotinib as first-line treatment for CML, and discuss the rationale for its routine use, as well as some possible future perspectives for CML patients...
  45. ncbi request reprint A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
    Michele Baccarani
    L and A Seràgnoli Institute of Hematology and Medical Oncology, S Orsola Hospital, University of Bologna, Italy
    Blood 99:1527-35. 2002
    ....